Case is a recent example of the trend toward Medicare schemes involving telehealth, cancer genetic testing, and kickbacks.
Subscribe today for access to
Articles and Reports
The agency’s latest report to Congress shows that while enforcement activity is returning to pre-pandemic levels, recoveries are still down.
The court recently denied the petition to hear a case that would have helped offer clarity on what evidence whistleblowers need to file qui tam lawsuits under the FCA.
After the DOJ announced a massive National Health Care Fraud Enforcement Action on July 20 targeting telehealth and telemarketing scams, labs need to be extremely wary, especially if they provide genetic testing.
While the report’s most significant findings involved labs and lab testing, it wasn’t just the usual finger pointing this time.
If your lab received federal relief funds from the US government during the COVID-19 pandemic, you could be at risk of FCA lawsuits.
UDT false billing cases seem to be on the rise again, accounting for a trio of recent multimillion dollar settlements.
MFCU enforcement activity has rebounded from recent declines but still hasn’t reached pre-pandemic levels, according to a recent OIG report.
Thanks to recent federal enforcement initiatives, prompt response to patient PHI requests should be a growing priority for HIPAA compliance.
Regulatory Roundup: New laws, regulations, cases, and enforcement actions affecting labs and the lab industry
This month’s roundup includes the continued court battle between BGI and Illumina, an FCA lawsuit, and the latest version of OSHA’s COVID-19 rule.
What happens when a whistleblower’s case is based on information that’s already been publicly disclosed?
The cost of recoveries hit an eight-year high in FY 2021, with the health care industry footing 90 percent of the bill.
Labs that bill federal health care programs for these tests need to pay especially close attention to ensure compliance.